{
    "clinical_study": {
        "@rank": "11714", 
        "arm_group": {
            "arm_group_label": "Pembrolizumab", 
            "arm_group_type": "Experimental", 
            "description": "Participants receive pembrolizumab 10 mg/kg, intravenously (IV), on Day 1 of every 2-week dosing cycle for up to 24 months"
        }, 
        "brief_summary": {
            "textblock": "This study will assess the efficacy and safety of pembrolizumab administered to participants\n      with incurable advanced biomarker-positive solid tumors that have not responded to current\n      therapy or for which current therapy is not appropriate. The hypothesis is that\n      administration of pembrolizumab to participants with some types of solid tumors will result\n      in a clinically meaningful response rate."
        }, 
        "brief_title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumor", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Histologically or cytologically documented locally-advanced and/or metastatic solid\n             malignancy that is incurable, and has failed prior standard therapy or for which\n             standard therapy is not appropriate\n\n          -  Have biomarker-positive solid tumor\n\n          -  Have measurable disease based on Response Criteria in Solid Tumors Version 1.1\n             (RECIST 1.1)\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1\n\n          -  Adequate organ function\n\n          -  Female participants of childbearing potential must be willing to use 2 methods of\n             birth control or be surgically sterile, or abstain from heterosexual activity for the\n             course of the study through 120 days after the last dose of study medication\n\n          -  Male participants must agree to use an adequate method of contraception starting with\n             the first dose of study therapy through 120 days after the last dose of study therapy\n\n        Exclusion Criteria:\n\n          -  Currently participating in or has participated in a study of an investigational agent\n             or using an investigational device within 4 weeks of the first dose of treatment\n\n          -  Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form\n             of immunosuppressive therapy within 7 days prior to the first dose of trial treatment\n\n          -  Prior anti-cancer therapy with a monoclonal antibody (mAb) within 4 weeks prior to\n             study Day 1 or not recovered from adverse events due to mAbs administered more than 4\n             weeks earlier\n\n          -  Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2\n             weeks (12 weeks for measurable sites of CNS disease) prior to study Day 1 or not\n             recovered from adverse events due to a previously administered agent\n\n          -  Known additional malignancy that is progressing or requires active treatment\n             excepting basal cell carcinoma of the skin, squamous cell carcinoma of the skin that\n             has undergone potentially curative therapy, or in situ cervical cancer\n\n          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n\n          -  Active autoimmune disease requiring systemic treatment within the past 3 months or a\n             documented history of clinically severe autoimmune disease, or a syndrome that\n             requires systemic steroids or immunosuppressive agents\n\n          -  Evidence of interstitial lung disease\n\n          -  Active infection requiring systemic therapy\n\n          -  Known psychiatric or substance abuse disorders that would interfere with cooperation\n             with the requirements of the trial\n\n          -  Pregnant, breastfeeding, or expecting to conceive or father children within the\n             projected duration of the trial, starting with the pre-screening or screening visit\n             through 120 days after the last dose of trial treatment\n\n          -  Prior therapy with an anti-PD-1, anti-PD-L1, and anti-PD-L2 (including ipilimumab or\n             any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint\n             pathways)\n\n          -  Known history of human immunodeficiency virus (HIV)\n\n          -  Known active Hepatitis B or Hepatitis C"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "320", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02054806", 
            "org_study_id": "3475-028", 
            "secondary_id": [
                "2013-004507-39", 
                "142515"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Pembrolizumab", 
            "intervention_name": "Pembrolizumab", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }, 
                    "name": "Call for Information (Investigational Site 0002)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "Call for Information (Investigational Site 0007)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }, 
                    "name": "Call for Information (Investigational Site 0005)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Call for Information (Investigational Site 0008)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rockville", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20850"
                    }, 
                    "name": "Call for Information (Investigational Site 0006)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Call for Information (Investigational Site 0004)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Brunswick", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08903"
                    }, 
                    "name": "Call for Information (Investigational Site 0009)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Call for Information (Investigational Site 0001)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Call for Information (Investigational Site 0070)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Call for Information (Investigational Site 0010)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Call for Information (Investigational Site 0003)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Medical Information Centre / Centre de l'information medicale de Merck Canada", 
                    "phone": "514-428-8600 / 1-800-567-2594"
                }, 
                "facility": {
                    "address": {
                        "city": "Kirkland", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H9H 3L1"
                    }, 
                    "name": "Merck Canada"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dominique Blazy", 
                    "phone": "33 147548990"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "MSD France"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Patrizia Nardini", 
                    "phone": "39 06 361911"
                }, 
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }, 
                    "name": "MSD Italia S.r.l."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Japan Call Center", 
                    "phone": "81-3-6272-1957"
                }, 
                "facility": {
                    "address": {
                        "city": "Chiyoda-Ku, Tokyo", 
                        "country": "Japan", 
                        "zip": "102-8667"
                    }, 
                    "name": "MSD K.K."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cem Ozesen", 
                    "phone": "90 212 3361260"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "MSD Korea LTD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Caroline Doornebos", 
                    "phone": "31 23 515 3362"
                }, 
                "facility": {
                    "address": {
                        "city": "Haarlem", 
                        "country": "Netherlands"
                    }, 
                    "name": "Merck Sharp & Dohme BV"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cesar Sanz Rodriguez", 
                    "phone": "34 913210600"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Merck Sharp and Dohme de Espana S.A."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paul Robinson", 
                    "phone": "44 1992452396"
                }, 
                "facility": {
                    "address": {
                        "city": "Hoddesdon", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Merck Sharp & Dohme Ltd."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "France", 
                "Italy", 
                "Japan", 
                "Korea, Republic of", 
                "Netherlands", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director, Study Director, Merck", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Best Overall Response Using Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)", 
            "safety_issue": "No", 
            "time_frame": "Up to 28 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02054806"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Duration of Response (DOR) in Participants Who Achieve Partial Response (PR) or Better", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}